We also assessed the prevalence of alterations that have been reported to impact response to HER2-directed therapies (mAb, TKI, and ADC) in ERBB2-amplified (ERBB2amp) versus ERBB2mut tumors across select cancer types (Fig. 3; Supplementary Fig. S10). Here, ERBB2 is linked to cancer.